OncoArendi Therapeutics SA (DE:1B1)

FRANKFURT:1B1

1B1

OncoArendi Therapeutics SA

RESEARCH TOOLSreports

OncoArendi Therapeutics SA (1B1) Price & Analysis

Compare

0 Followers

1B1 Stock Chart & Stats

€1.20

-€0.10(-4.45%)

At close: Jan 08 4:00 PM EST

€1.20

-€0.10(-4.45%)

Day’s Range― - ―

52-Week Range€1.20 - €2.17

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€24.64M

Enterprise Value€94.84M

Total Cash (Recent Filing)€16.35M

Total Debt (Recent Filing)€5.29M

Price to Earnings (P/E)―

Beta0.35

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding20,603,155

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)1.54

Price to Sales (P/S)0.00

P/FCF Ratio-6.95

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

1B1 FAQ

What was OncoArendi Therapeutics SA’s price range in the past 12 months?

OncoArendi Therapeutics SA lowest stock price was €1.20 and its highest was €2.17 in the past 12 months.

What is OncoArendi Therapeutics SA’s market cap?

OncoArendi Therapeutics SA’s market cap is €24.64M.

When is OncoArendi Therapeutics SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were OncoArendi Therapeutics SA’s earnings last quarter?

Currently, no data Available

Is OncoArendi Therapeutics SA overvalued?

According to Wall Street analysts OncoArendi Therapeutics SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoArendi Therapeutics SA pay dividends?

OncoArendi Therapeutics SA does not currently pay dividends.

What is OncoArendi Therapeutics SA’s EPS estimate?

OncoArendi Therapeutics SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoArendi Therapeutics SA have?

OncoArendi Therapeutics SA has 20,603,155 shares outstanding.

What happened to OncoArendi Therapeutics SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OncoArendi Therapeutics SA?

Currently, no hedge funds are holding shares in DE:1B1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoArendi Therapeutics SA

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.